Post-earnings recap
Reported
Tue, May 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Xenon Pharmaceutical's earnings report shows a loss per share of $0.43, with no revenue figures disclosed. The stock reacted negatively, dropping 2.35%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's direction without specific targets.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to ongoing projects.
Management did not provide specific guidance for future quarters.
The company remains focused on its ongoing clinical trials.